IL1B and Stroke: Moreover, CANTOS trials resulted in a decreased number of cardiovascular deaths, the risk of major adverse cardiovascular events, non-fatal stroke, and non-fatal myocardial infarction in response to the use of canakinumab, which acts as the selective inhibitor of IL1.